CN105477071A - Medicine composition for treating encephalanalosis and preparation method thereof - Google Patents

Medicine composition for treating encephalanalosis and preparation method thereof Download PDF

Info

Publication number
CN105477071A
CN105477071A CN201610047234.0A CN201610047234A CN105477071A CN 105477071 A CN105477071 A CN 105477071A CN 201610047234 A CN201610047234 A CN 201610047234A CN 105477071 A CN105477071 A CN 105477071A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
ethanol
weight
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047234.0A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047234.0A priority Critical patent/CN105477071A/en
Publication of CN105477071A publication Critical patent/CN105477071A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a medicine composition for treating encephalanalosis and a preparation method thereof. The medicine composition is prepared by compounding the following crude drugs according to a ratio: fruits of eucalyptus globules, lysimachia hemsleyana, sanggenone D, centaurium erythraea and Okanin, can be made into various dosage forms according to the conventional preparation technology, and is obvious in the curative effect of treating encephalanalosis.

Description

Pharmaceutical composition for the treatment of brain atrophy and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of brain atrophy and preparation method thereof.
Background technology
Brain atrophy refers to because a variety of causes causes cerebral tissue itself that organic disease occurs and produces a class neuropsychiatric disease of atrophy.Brain atrophy comprises Cerebral Atrophy in Children, Adult Human Brain atrophy.Common with old people.Atrophy is dull-witted in clinical topmost symptom, especially old people Yi Yinqi senile dementia.Brain atrophy belongs to the category such as the traditional Chinese medical science " dementia ", " forgetful ", " dizzy ", " myopathy ", " trembling ".Though the traditional Chinese medical science thinks that the sick position of primary disease is at brain, closely related with each function, pathomechanism belongs to deficiency in origin and excess in superficiality.
Brain atrophy adult onset: be multiplely born in more than 50 years old, the course of disease can reach the several years to many decades, male is more than women, and brain atrophy has diffuse brain atrophy (comprising cortical atrophy, cerebellar atrophy and cortex, cerebellum, brain stem atrophy) and circumscribed cerebral atrophy (be more common in after limitation brain organic pathological changes as after wound, angiopathy, intracranial localized infection etc.).Because its cause of disease is complicated, onset is slow, and not easily realized, the course of disease is long, makes slow progress, and may increase the weight of gradually, affects orthobiosis and the work of patient.Discovery early, actively suitable symptom management and further treatment are significant.Patient does not obviously show in early days in disease, therefore during general discovery, it is in late period.Now the brain tissue of patient has shown as situation about obviously reducing, and now the doctor trained in Western medicine effect of carrying out treating is undesirable.The traditional Chinese medical science does not describe this disease, but its symptom and tremble, myopathy, dizzy, asthenia have dependency, belong in the category of this type of disease.Its pathogeny is the prolonged illness deficiency of vital energy, deficiency of the liver and kindey, lack of preservation of spirit, brains do not fill; Or old renal failure, can not fill marrow by spermatogenesis, brain is hollow, brain key cervical carcinoma with cachexia; Or edema with the liver involved is lost and dredged, gram cut down spleen soil, dysfunction of the spleen in transportation, it is micro-that water paddy can not change spermatogenesis, and QI-blood failing to nourish upward is in brain, and anti-raw expectorant is turbid, hoodwinks key and cause primary disease clearly.The treatment of primary disease, current modern medicine can only treat its mental symptom, is difficult to the feature of curing its " deficiency of marrow-reservoir " and " brains are gradually empty ".Take a broad view of primary disease, the origin cause of formation has deficiency and excess two ends, deficiency in origin and mark reality.Brain atrophy incidence of occult, early symptom is not obvious, difficulty is brought to prevention and early diagnosis, brain atrophy belongs to chronic disease, pathogen usually intruding into collateral in protracted disease, deficiency in both YIN and YANG, folder card of holding concurrently is complicated, the complexity of its pattern of syndrome, polytropy brings difficulty to clinical syndrome differentiation treatment, early screening is carried out to brain atrophy high-risk group, intervene, find early and symptom management, treatment must aim at the pathogenesis of disease is a large feature of Chinese traditional treatment, for the treatment of primary disease, for its main pathological change carry out dialectical treat particularly important, the performance of reason mainly due to primary disease of Endodontic failure is intricate, grab clinically incessantly caused by Etiological pathogenesis.Therefore, must the labor cause of disease, medical history, symptom, all items of tongue arteries and veins, see through the appearance to perceive the essence, otherwise the principle and meaning that the traditional Chinese medical science cures the disease can be lost.
Herba centaurll altaici: this product is Gentianaceae centaurium Centaurium meyeri Druce CentauriumpulchellumDrucevar.al-taicum(Griseb.) Kitag.etHara [Erythraearamosissimavar.al-taicaGriseb.; Centauriummeyeri(Bunge) Druce ］ wounded in the battle herb.Gather when blooming, dry.[nature and flavor] are bitter; Cold in nature.[return through] liver; Stomach warp.[function cures mainly] heat-clearing and toxic substances removing.Main hepatitis; Cholecystitis; Have a headache and fever; Toothache; Tonsillitis.[former phytomorph] annual herb, high 20 ~ 30 centimetres.Stem four prismatic, has branch.Leaf is to life, and stockless, lanceolar, grows 1.5 ~ 2 centimetres, wide 4 ~ 6 millimeters.Flower axil is raw or top is raw, and spend more, calyx 5 splits; Corolla white or lavender, 5 split, and cylindrical fireworks are elongated; Stamen 5, flower pesticide Long Circle, Post flowering is curling in the shape of a spiral.Capsule long column shape, florescence 7 ~ JIUYUE.Record in Chinese medicine voluminous dictionary.
Eucalyptus fruit: this product is the fruit of myrtle Eucalyptus globulus Labill EucalyptusglobulusLabill..Gather when summer or fruit maturation in winter, dry.[nature and flavor] acrid in the mouth; Bitter; Slightly warm in nature; Mild toxicity.[function cures mainly] regulates the flow of vital energy; Stomach invigorating; Plant malaria; Antipruritic.Staple food amasss; Abdominal distention; Malaria; Dermatitis; Tinea skin ulcer.[former phytomorph] Eucalyptus globulus Labill, evergreen megaphanerophyte.Bark dusty blue, peels off toward shape; Twig is rib slightly.Young tender leaf is to life; Blade is avette, and base portion is heart-shaped, and stockless, has white lead; Growth blade keratin, lanceolar, falciform, long 15-30cm, wide 1-2cm, there is gland point on two sides, the long 1.5-3cm of petiole, slightly flat.Hua great, white, footpath is about 4cm, and single life or 2-3 consor are in axil; Without bennet or extremely short; Calyx pipe turbination, long 1cm, wide 1.3cm, surface has 4 projection corner angle and tubercle to close projection, by white lead; Calyptra is slightly flat, and middle part is conical papilla, shorter than calyx pipe, 2 layers, outer level and smooth, caducous; Stamen is most, long 8-13mm, multiple row, and filigree is very thin, and is born in the middle part of flower pesticide, and flower pesticide is oval, wealthy ear lobe; Ovary and the symphysis of calyx pipe, the long 7-8mm of style is thick.Capsule hemispherical, has 4 ribs, wide 2-2.5cm, and fruit edge is flat and wide, and fruit lobe is not given prominence to.Fruit summer phase and winter.Record in Chinese medicine voluminous dictionary.
Lysimachia hemsleyana: this product is the herb of Primulaceae Lysimachia plant Lysimachia hemsleyana LysimachiahemsleyanaMaxim..Summer gathers, and dries.[nature and flavor] micro-hardship; Cool in nature.[function cures mainly] clearing away heat-damp and promoting diuresis; Stimulate the menstrual flow.Main hepatitis; Pyelonephritis; Cystitis; Amenorrhea.Isolate potassium chloride and mixing saccharide in [chemical analysis] herb, preliminary examination still has the reactions such as flavonoid, Saponin, glycoside, lactone and organic acid.[pharmacological action] choleretic effect rat oral 100% Lysimachia hemsleyana decoct 5m1 every day, in continuous 6 weeks, in general anesthesia acute experiment situation, compares with matched group, has the effect promoting bile excretion.As lower in dosage or eye is short with the phase, then act on not obvious, continuous eye decoct is after 2-3 days, and animal feces is thinning, and color becomes sepia, but does not find intoxicating phenomenon.Rat without gallbladder, therefore promotes that the excretion of bile is not caused by enhancing gallbladder contraction.Record in Chinese medicine voluminous dictionary.
Coreopsis basalis chalcone derivative (Okanin): CAS 484-76-4, molecular formula C 15h 12o 6, molecular weight 288.26.[pharmacological action] flavochrome.In [ingredient origin] Compositae golden pheasant Chrysanthemum and Bidens plant Hemerocallis citrina Baroni.
Saliggenon D (SanggenonD): CAS 81422-93-7, molecular formula C 40h 36o 12, molecular weight 708.71.[pharmacological action] resisting hypertension (rat iv, 0.5 ~ 2.0mg/kg); Suppress arachidonic acid metabolism (rat platelet aggregation is concentrated, and suppresses the formation of TXB2, IC50=48.3umo/L); CAMP phosphodiesterase inhibitor (IC50=26gmol/L).[ingredient origin] Cortex Mori Morusalba.
The structure of 2 crude drug:
Saliggenon D (SanggenonD) Coreopsis basalis chalcone derivative (Okanin).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment brain atrophy and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment brain atrophy are:
Eucalyptus fruit 3100-3300 weight portion Lysimachia hemsleyana 2800-2900 weight portion Saliggenon D 40-80 weight portion Herba centaurll altaici 1400-1600 weight portion Coreopsis basalis chalcone derivative 30-50 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of brain atrophy, be made up of the crude drug of following weight portion:
Eucalyptus fruit 3200 weight portion Lysimachia hemsleyana 2850 weight portion Saliggenon D 60 weight portion Herba centaurll altaici 1500 weight portion Coreopsis basalis chalcone derivative 40 weight portions.
Treat a pharmaceutical composition for brain atrophy, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for brain atrophy, it is characterized in that the treatment brain atrophy medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of brain atrophy, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Eucalyptus fruit 3100-3300 weight portion Lysimachia hemsleyana 2800-2900 weight portion Saliggenon D 40-80 weight portion Herba centaurll altaici 1400-1600 weight portion Coreopsis basalis chalcone derivative 30-50 weight portion;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of brain atrophy, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Eucalyptus fruit 3200 weight portion Lysimachia hemsleyana 2850 weight portion Saliggenon D 60 weight portion Herba centaurll altaici 1500 weight portion Coreopsis basalis chalcone derivative 40 weight portions;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of brain atrophy, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of brain atrophy, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat brain atrophy medicine.
Medicine composite for curing brain atrophy is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of brain atrophy and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are: Eucalyptus fruit 3200g Lysimachia hemsleyana 2850g Saliggenon D 60g Herba centaurll altaici 1500g Coreopsis basalis chalcone derivative 40g;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of brain atrophy and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are: Eucalyptus fruit 3100g Lysimachia hemsleyana 2900g Saliggenon D 40g Herba centaurll altaici 1600g Coreopsis basalis chalcone derivative 30g;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of brain atrophy and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are: Eucalyptus fruit 3300g Lysimachia hemsleyana 2800g Saliggenon D 80g Herba centaurll altaici 1400g Coreopsis basalis chalcone derivative 50g;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 422g, adds starch 172g, mixing, granulates, dry, adds microcrystalline Cellulose 62g, magnesium stearate 3.2g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 233g, adds starch 133g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 231g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 18g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 7 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.2cm apart from liquid level, drips speed with per minute 45 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of brain atrophy
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are:
Eucalyptus fruit 3113 weight portion Herba centaurll altaici 2512 weight portion Coreopsis basalis chalcone derivative 46 weight portions.
Embodiment 8: the pharmaceutical composition for the treatment of brain atrophy
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are:
Saliggenon D 32 weight portion Herba centaurll altaici 2530 weight portion Coreopsis basalis chalcone derivative 38 weight portion.
Embodiment 9: the pharmaceutical composition for the treatment of brain atrophy
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of brain atrophy are:
Saliggenon D 35 weight portion Herba centaurll altaici 2582 weight portion Coreopsis basalis chalcone derivative 53 weight portion.
Experimental example 1: the experimental study for the treatment of brain atrophy
1 object and method
1.1 physical data
In March ,-2012 in February, 2011 is treated 34 routine Brain Atrophy Patients by the measure of differentiation of tcm, and wherein 17 routine patients are male, and 17 routine patients are women, and the course of disease of patient disease is 5 months-5 years.Cranial Computed Tomography scanning is shown: gyrus narrows, the ventricles of the brain expand, and brain ditch is broadening.
1.2 method
All patients all carry out differential diagnosis in tcm opinion and treat.Be divided in expectorant heat disturb, the turbid retardance of expectorant, qi depression to blood stasis, deficiency of both the heart and spleen, the hepatic and renal YIN deficiency five type, give its for pharmaceutical composition treat.
1.2.1 patient disturbs type brain atrophy in expectorant heat
Stringy and rolling pulse, yellow fur and thick greasy, red tongue with a little fluid, implication dirty smelly, constipation, anorexia can be had, forget the clinical manifestations such as indifferent, language repeats, night sleeps sleeplessness, Blushing, irritable rage, persistent wilfulness, personality odd habit, mind are stupid.
Patient on medication's compositions (embodiment 1 pharmaceutical composition lot number 20101028), each 0.5g, 3 times on the one.
1.2.2 patient is phlegm blockage brain atrophy
Patient can have that soft pulse is sliding, tongue in vain greasy, the general sputum of gums, pale tongue, mouth, both hands tremble, instability of gait, not hungry, slurred speech, insomnia, dizziness uncomfortable in chest, breathe hard, the clinical manifestation such as cardiopalmus, amnesia.
Patient on medication's compositions (embodiment 2 pharmaceutical composition lot number 20101026), each 0.5g, 3 times on the one.
1.2.3 patient is qi stagnation and blood stasis type brain atrophy
The clinical manifestations such as patient can have stringy and thready pulse, white and thin fur, body of the tongue dim red, constipation, inarticulateness, irritability, agitation, hemiplegia, trembles, is slow in action, deaf aphasia, uncomfortable in chest, forgetful, the insomnia of having a headache, look stiff.
Patient on medication's compositions (embodiment 3 pharmaceutical composition lot number 20101027), each 0.5g, 3 times on the one.
1.2.4 patient is type of deficiency of both the heart and spleen brain atrophy
Patient can have deep-slow pulse, tongue in vain greasy, light red tongue is fat, edema of lower limbs, urinary incontinence, slobbering, anorexia loose stool, melancholy few dynamic, reticent aphasia, mind stay the clinical manifestations such as tired.
Patient on medication's compositions (embodiment 1 pharmaceutical composition lot number 20101029), each 0.5g, 3 times on the one.
1.2.5 patient is liver-kidney yin deficiency brain atrophy
Patient can have dizzy, blunt forgetful, the clinical manifestation such as emotion is irritable, personality is stubborn of thready and rapid pulse, red tongue with a little fluid, insomnia irritability, suspicious kind worry, blurring of vision, Hiccough and deaf, headache.Treat with beneficial marrow, replenishing essence, invigorating the liver and kidney as Therapeutic Principle.
Patient on medication's compositions (embodiment 1 pharmaceutical composition lot number 20101028), each 0.5g, 3 times on the one.
All patients all give the treatment of 10 days, and midfeather is treated for 5 days again.
1.3 evaluation index
1. cure: the every condition improved of patient after treatment, minimal invasive treatment can take care of oneself, and follows up a case by regular visits to patient, and the time is 2 years, and situation about recurring does not appear in its disease.
2. take a turn for the better: the clinical manifestation of patient improves through treatment, and minimal invasive treatment can take care of oneself, and to follow-up of patients, it had the situation of recurrence to occur in 6 months.
3. invalid: patient feels its clinical manifestation and makes moderate progress, but inspection not change is carried out to patient.
2 results
Cure 18 examples and account for 52.94%; 14 examples that take a turn for the better account for 41.18%; 2 routine patients are invalid, account for 5.88%.
The total effective rate for the treatment of is 94.12%.
Cure Take a turn for the better Invalid Total effective rate (%) 6-->
Medicine composite for curing 18 14 2 94.12
Result shows, medicine composite for curing brain atrophy is evident in efficacy.

Claims (8)

1. treat a pharmaceutical composition for brain atrophy, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Eucalyptus fruit 3100-3300 weight portion Lysimachia hemsleyana 2800-2900 weight portion Saliggenon D 40-80 weight portion Herba centaurll altaici 1400-1600 weight portion Coreopsis basalis chalcone derivative 30-50 weight portion.
2. a kind of pharmaceutical composition for the treatment of brain atrophy according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Eucalyptus fruit 3200 weight portion Lysimachia hemsleyana 2850 weight portion Saliggenon D 60 weight portion Herba centaurll altaici 1500 weight portion Coreopsis basalis chalcone derivative 40 weight portions.
3. a kind of pharmaceutical composition for the treatment of brain atrophy according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of brain atrophy according to claim 1, is characterized in that the treatment brain atrophy medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of brain atrophy, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Eucalyptus fruit 3100-3300 weight portion Lysimachia hemsleyana 2800-2900 weight portion Saliggenon D 40-80 weight portion Herba centaurll altaici 1400-1600 weight portion Coreopsis basalis chalcone derivative 30-50 weight portion;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of brain atrophy according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Eucalyptus fruit 3200 weight portion Lysimachia hemsleyana 2850 weight portion Saliggenon D 60 weight portion Herba centaurll altaici 1500 weight portion Coreopsis basalis chalcone derivative 40 weight portions;
Preparation method:
(1) Eucalyptus fruit is got by crude drug proportioning, Lysimachia hemsleyana, Saliggenon D, Herba centaurll altaici, Coreopsis basalis chalcone derivative, mixing, with weight percent concentration 17% ethanol as solvent, extract at 32 DEG C of warm macerating, extraction time is 11 times, each extraction time is 2.5 hours, each solvent load is 29.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by D102 macroporous adsorptive resins, first wash with water, use weight percent concentration 57.5% alcoholic solution eluting D102 macroporous adsorptive resins again, collect weight percent concentration 57.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 39% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of brain atrophy according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of brain atrophy according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats brain atrophy medicine.
CN201610047234.0A 2016-01-25 2016-01-25 Medicine composition for treating encephalanalosis and preparation method thereof Withdrawn CN105477071A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047234.0A CN105477071A (en) 2016-01-25 2016-01-25 Medicine composition for treating encephalanalosis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047234.0A CN105477071A (en) 2016-01-25 2016-01-25 Medicine composition for treating encephalanalosis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105477071A true CN105477071A (en) 2016-04-13

Family

ID=55664586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047234.0A Withdrawn CN105477071A (en) 2016-01-25 2016-01-25 Medicine composition for treating encephalanalosis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105477071A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106668183A (en) * 2016-12-10 2017-05-17 济南昊雨青田医药技术有限公司 Pharmaceutical composition for treating epilepsy and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106668183A (en) * 2016-12-10 2017-05-17 济南昊雨青田医药技术有限公司 Pharmaceutical composition for treating epilepsy and preparation method thereof

Similar Documents

Publication Publication Date Title
CN105343625A (en) Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof
CN104398986A (en) Tranquilization and brain tonifying epimedium herb oral liquid and preparation method thereof
CN104208245B (en) Tinea manus and pedis Traditional Chinese medicine medicated bath and preparation method
CN103463297B (en) A kind of Chinese medicine composition for the treatment of eczema scrotum and its production and use
CN102861287B (en) Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof
CN102772781A (en) Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof
CN105213941A (en) A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof
CN101095923B (en) Chinese traditional medicine for treating ectopic pregnancy
CN103751568B (en) A kind of Chinese medicine composition treating pruritus and preparation method thereof
CN104127702A (en) Traditional Chinese medicine preparation for treating acute optic neuritis, as well as preparation method thereof
CN106109564A (en) Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
CN105535495A (en) Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method
CN105477071A (en) Medicine composition for treating encephalanalosis and preparation method thereof
CN103655786A (en) Traditional Chinese medicine composition for treating hyperuricemia and gout
CN103520643B (en) A kind of Chinese medicine preparation being used for the treatment of diabetic cataract and preparation method thereof
CN103705639B (en) One treats hydrocephalic Chinese medicine preparation
CN103007145B (en) Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition
CN105169216A (en) Pharmaceutical preparation for treating transient ischemic attack with syndrome of blood stasis in orifices and preparation method of pharmaceutical preparation
CN105031329A (en) Traditional Chinese medicine preparation used for treating liver qi stagnation-type hemicranias, and preparation method thereof
CN102228596B (en) Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris
CN105535177A (en) Medicine composition for treating encephalatrophy and preparation method of medicine composition
CN104027719A (en) Traditional Chinese medicine compound composition capable of treating hypersplenism liver-depression and spleen-deficiency type diseases caused by infectious endocarditis and preparation method thereof
CN109771567A (en) A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN104587078A (en) Traditional Chinese medicine preparation for treating viral pharyngitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160413